Corcept Therapeutics Inc Sustainability Reports
Corcept Therapeutics Incorporated discovers and develops medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of the stress hormone cortisol. Its first approved product, Korlym, is used for the treatment of patients with Cushing's syndrome.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 529900EO9LUTFMZ7FF90
FIGI: BBG001S8QGV1
1 reports from 2017 to 2017
